Lantern Pharma Inc Asset Resilience Ratio
Lantern Pharma Inc asset resilience ratio. Lantern Pharma Inc (LTRN) has an Asset Resilience Ratio of 8.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LTRN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lantern Pharma Inc (2020–2025)
Asset resilience ratio of Lantern Pharma Inc from 2020 to 2025. This chart shows how Lantern Pharma Inc's Asset Resilience Ratio has changed over time. Read Lantern Pharma Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lantern Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lantern Pharma Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $701.09K | 8.15% |
| Total Liquid Assets | $701.09K | 8.15% |
Asset Resilience Insights
- Limited Liquidity: Lantern Pharma Inc maintains only 8.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lantern Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Lantern Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Lantern Pharma Inc Asset Resilience Ratio by Year (2020–2025)
Lantern Pharma Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Lantern Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.62% | $5.70 Million | $11.04 Million | -12.91pp |
| 2024-12-31 | 64.53% | $16.50 Million | $25.57 Million | +20.17pp |
| 2023-12-31 | 44.37% | $19.36 Million | $43.65 Million | +13.78pp |
| 2022-12-31 | 30.58% | $17.99 Million | $58.84 Million | +4.62pp |
| 2021-12-31 | 25.96% | $19.20 Million | $73.95 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $20.36 Million | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more